Phenylbutazone: Efficacy as a Historical NSAID

Phenylbutazone (trade name Ambene and generics) is a non-steroidal anti-inflammatory drug (NSAID) from the pyrazolidinedione class. Known since the 1950s, phenylbutazone has historically played an important role in treating rheumatic diseases. Due to severe hematological adverse effects such as agranulocytosis and aplastic anemia, its range of use in Germany was severely restricted in the 1980s. Today, phenylbutazone is a reserve therapy considered exclusively for acute exacerbations of ankylosing spondylitis (Bechterew disease) and acute gout attacks when other NSAIDs fail.

In clinical practice, phenylbutazone is prescribed only very rarely. Modern NSAIDs such as ibuprofen, naproxen, diclofenac, or coxibs have largely replaced phenylbutazone because they offer significantly better safety profiles with comparable efficacy. Those who nonetheless receive phenylbutazone therapy require strict medical supervision with regular blood count monitoring and short treatment duration.

Mechanism of Action

Phenylbutazone non-selectively inhibits cyclooxygenases COX 1 and COX 2, thereby reducing the formation of pro-inflammatory prostaglandins. This results in potent anti-inflammatory, analgesic, and antipyretic effects. Additionally, phenylbutazone inhibits tubular reabsorption of uric acid and acts uricosuric, explaining its use in acute gout attacks.

Compared to modern NSAIDs, the anti-inflammatory potency of phenylbutazone is high. However, non-selective COX inhibition carries a high risk of gastrointestinal bleeding and cardiovascular events. Particularly critical is the risk of hematological toxicity: phenylbutazone can trigger severe agranulocytosis, which occurs idiosyncratically (not dose-dependent) and in approximately one in ten thousand to thirty thousand patients leads to life-threatening granulocytopenia.

Pharmacokinetically, phenylbutazone demonstrates a very long half-life of 50 to 100 hours. This prolonged duration of action contributes to accumulation and requires careful dosing. Metabolism occurs primarily hepatically via CYP enzymes. Phenylbutazone is a strong inducer of various CYP enzymes and simultaneously an inhibitor of some metabolic pathways, explaining numerous drug interactions.

Indications

• Acute exacerbation of ankylosing spondylitis (Bechterew disease), when other NSAIDs show insufficient efficacy
• Acute gout attack, as reserve therapy when other NSAIDs or colchicine fail
• Reactive arthritis in specific constellations, very restrictively

Phenylbutazone is NOT suitable for chronic pain management, osteoarthritis, ordinary back pain, headaches, or mild symptoms. In all these indications, other NSAIDs with significantly better safety profiles are preferable. Self-medication is not an option because phenylbutazone is prescription-only.

Dosage and Administration

Adults: initially 600 mg per day divided into three single doses. After 1 to 2 days, reduce to 300 mg per day. Maximum treatment duration 7 days.

Acute gout attack: 400 to 600 mg on the first day, then reduction. Not longer than one week.

Administration: with meals or milk to reduce gastrointestinal discomfort, with plenty of water. Swallow tablets whole.

Renal impairment: contraindicated in reduced renal function or requires significant dose reduction. Hepatic impairment: contraindicated in moderate to severe impairment.

Treatment duration: very short, generally maximum 7 days. Longer use is not indicated due to hematological risks.

Gastric protection: concomitant therapy with a proton pump inhibitor is recommended in at-risk patients and in general for phenylbutazone therapy.

Storage: prescription-only, store in locked cabinet at home.

Adverse Effects

Common: gastrointestinal complaints including nausea, vomiting, abdominal pain, heartburn, gastric erosions and ulcers. Fluid retention with edema, weight gain.

Occasional: rash, pruritus, elevation of liver transaminases, hypertension, deterioration of renal function.

Rare but life-threatening: agranulocytosis with granulocyte deficiency and severe infections, aplastic anemia with pancytopenia. These hematological complications are idiosyncratic and can occur even at low doses. They are the primary reason for restricted use.

Stevens Johnson Syndrome and toxic epidermal necrolysis (TEN) are very rare but life-threatening severe cutaneous reactions.

Thromboembolic events such as stroke or myocardial infarction are described generally with NSAIDs, possible with phenylbutazone, especially with prolonged use.

In elderly patients: increased risk of gastrointestinal bleeding, renal insufficiency, heart failure, and hematological complications. Use in geriatrics is considered critical.

Drug Interactions

• Vitamin K antagonists (warfarin, phenprocoumon): Phenylbutazone displaces them from plasma protein binding and inhibits their metabolism. INR increases significantly, bleeding risk very high. Combination contraindicated or only under very close monitoring.
• Sulfonylureas (glibenclamide, glimepiride): enhanced hypoglycemic effects with risk of severe hypoglycemia.
• Phenytoin and other antiepileptics: phenylbutazone inhibits their metabolism, neurotoxic symptoms possible.
• Lithium: elevated lithium levels with risk of lithium intoxication.
• Methotrexate: increased methotrexate toxicity through reduced renal clearance.
• Other NSAIDs and glucocorticoids: additive gastrointestinal bleeding risk, avoid combination.
• ACE inhibitors and diuretics: reduced antihypertensive effect, risk of acute renal insufficiency (Triple Whammy with combination of diuretic and ACE inhibitor).
• Other myelotoxic substances: additive bone marrow damage.

Special Precautions

Pregnancy: Phenylbutazone is contraindicated in pregnancy, especially in the third trimester, because of risk of premature closure of the ductus arteriosus in the fetus. Breastfeeding: transfer into breast milk, use not recommended.

Children and adolescents: not approved.

Elderly patients: very restrictive use due to increased risks of hematological complications, gastrointestinal bleeding, and renal insufficiency. Listed on the Priscus 2.0 List as potentially inappropriate medication in older adults.

Before starting therapy: complete blood count with differential, liver function tests, renal function tests, bilirubin, electrolytes, history of gastrointestinal disease, cardiovascular risk factors, allergies.

Monitoring: blood count before therapy, after 1 week and when adverse effects are suspected such as fever, sore throat, fatigue, or bleeding tendency. If granulocytes fall below 1500 per microliter, immediately discontinue therapy and seek medical attention.

Patient counseling: symptoms such as unexplained fever, sore throat, unusual fatigue, bleeding tendency, or small petechial hemorrhages require immediate medical evaluation because they may indicate agranulocytosis or pancytopenia.

Lifestyle: for chronic rheumatic diseases, exercise, physiotherapy, and if applicable biologics or DMARDs are part of modern therapy. Phenylbutazone is only short-term acute therapy.

Driving ability: restricted if dizziness, visual disturbances, or confusion occur, individual assessment required.

You Might Also Be Interested In

• Dexketoprofen, modern NSAID with better safety profile
• Indomethacin, classic NSAID
• Piroxicam, long-acting NSAID
• Colchicine, alternative agent in acute gout attack
• Methotrexate, DMARD in rheumatic diseases

Frequently Asked Questions

Sources

• Gelbe Liste, Phenylbutazone Active Ingredient Profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines on Ankylosing Spondylitis and Gout Attack
• Priscus 2.0 List, Potentially Inappropriate Medication in Older Adults